Abstract | PURPOSE: MATERIALS AND METHODS: RESULTS: During a 3-year period, a total of 45 courses of high-dose In-111 octreotide treatment were delivered to 14 patients. In seven patients receiving an average of four treatment courses (6 carcinoid tumors, 1 thymoma, patients: 2, 4, 5, 11-14) stable disease was achieved (50%). In two patients with carcinoid tumors (patients 1 and 3) who received four treatment courses, partial response was observed (14%). Five patients (36%; 4 NET, 1 gastrinoma; patients 6-10) died due to progressive disease following on average two treatment courses. On average, deaths occurred 2 months after the last treatment dose. No complete responses were seen. Partial response was achieved in two of the nine patients receiving Sandostatin LAR, while four had stable disease. Both treatments were associated with acceptable tolerability. CONCLUSIONS: High-dose In-111 octreotide can be safely administered in conjunction with somatostatin analogue in patients with disseminated NET and this treatment may help to stabilize the disease.
|
Authors | Elgin Ozkan, Emel Tokmak, N Ozlem Kucuk |
Journal | Annals of nuclear medicine
(Ann Nucl Med)
Vol. 25
Issue 6
Pg. 425-31
(Jul 2011)
ISSN: 1864-6433 [Electronic] Japan |
PMID | 21476058
(Publication Type: Journal Article)
|
Chemical References |
- indium-111-octreotide
- Octreotide
|
Topics |
- Adult
- Aged
- Female
- Humans
- Male
- Middle Aged
- Neuroendocrine Tumors
(pathology, radiotherapy)
- Octreotide
(adverse effects, analogs & derivatives, therapeutic use)
- Radiation Dosage
- Radiotherapy Dosage
- Retrospective Studies
- Treatment Outcome
|